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The barrier to curing HIV-1 is thought to reside pri-
marily in CD4+ T cells containing silent proviruses.
To characterize these latently infected cells, we stud-
ied the integration profile of HIV-1 in viremic progres-
sors, individuals receiving antiretroviral therapy, and
viremic controllers. Clonally expanded T cells repre-
sented the majority of all integrations and increased
during therapy. However, none of the 75 expanded
T cell clones assayed contained intact virus. In
contrast, the cells bearing single integration events
decreased in frequency over time on therapy, and
the surviving cells were enriched for HIV-1 integra-
tion in silent regions of the genome. Finally, there
was a strong preference for integration into, or in
close proximity to, Alu repeats, which were also en-
riched in local hotspots for integration. The data indi-
cate that dividing clonally expanded T cells contain
defective proviruses and that the replication-compe-
tent reservoir is primarily found in CD4+ T cells that
remain relatively quiescent.
INTRODUCTION
Despite effective therapy, HIV-1 can persist in a latent state as an
integrated provirus in resting memory CD4+ T cells (Chun et al.,
1997; Finzi et al., 1997; Wong et al., 1997). The latent reservoir
is established very early during infection, (Chun et al., 1998),
and because of its long half-life of 44 months (Finzi et al.,
1999), it is the major barrier to curing HIV-1 infection (Siliciano
and Greene, 2011).
The HIV-1 latent reservoir has been difficult to define, in part
because reactivation of latent viruses is difficult to induce and420 Cell 160, 420–432, January 29, 2015 ª2015 Elsevier Inc.to measure. Viral outgrowth assays underestimate the size of
the reservoir, while direct measurements of integrated HIV-1
DNA overestimate the reservoir because a large fraction of the
integrated viruses are defective (Ho et al., 2013). Although the
latent reservoir remains to be completely defined, establishing
the reservoir requires intact retroviral integration into the genome
and subsequent transcriptional silencing (Siliciano and Greene,
2011). Whether or not the genomic location of the integration im-
pacts on latency is debated (Jordan et al., 2003; Jordan et al.,
2001; Sherrill-Mix et al., 2013). However, HIV integration into
the genome is known to favor the introns of expressed genes
(Han et al., 2004), some of which, like BACH2 and MKL2, carry
multiple independent HIV-1 integrations in different individuals
and are considered hotspots for integration (Ikeda et al., 2007;
Maldarelli et al., 2014; Wagner et al., 2014). However, there is
currently no precise understanding of the nature of these hot-
spots or why they are targeted by HIV-1.
Viremia rebounds from the latent reservoir after interruption of
long-term treatment with combination anti-retroviral therapy
(cART). When it does, it appears to involve an increasing pro-
portion of monotypic HIV-1 sequences, suggesting the prolifer-
ation of latently infected cells (Wagner et al., 2013). Based on
this observation and the finding that a subset of cells bearing
integrated HIV-1 undergoes clonal expansion in patients
receiving suppressive anti-retroviral therapy, it has been pro-
posed that the clonally expanded cells play a critical role in
maintaining the reservoir (Maldarelli et al., 2014; Wagner
et al., 2014).
To obtain additional insights into the regions of the genome
that are favored by HIV-1 for integration and the role of clonal
expansion in maintaining the reservoir, we developed a single
cell method to identify a large number of HIV-1 integration sites
from treated and untreated individuals, including ‘‘viremic con-
trollers’’ who spontaneously maintain viral loads of <2,000 RNA
copies/ml and ‘‘typical progressors’’ who display viral loads
>2,000 RNA copies/ml.
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Figure 1. HIV-1 Integration Libraries
(A) Diagram of integration library construction.
(B) Table of unique integrations identified in viremic controllers (C), viremic untreated progressors (V), and treated progressors (T).
(C) Proportion of integrations (Int) that are in genic or intergenic regions.
(D) Proportion of genic integrations located in introns.
(E) Proportion of integrations in genes with high, medium, or low expression. p values refer to proportion of integrations in highly expressed genes.
(F) Transcriptional orientation of integrated HIV-1 relative to host gene. ns, not significant.
*p < 0.05; **p < 0.01; ***p < 0.0001 using two-proportion z test. See also Figure S1.RESULTS
Integration Library Construction
Twenty-four integration libraries were constructed from CD4+
T cells from 13 individuals: three provided longitudinal samples
before and after (0.1–7.2 years) initiation of therapy; four were un-
treated; twowere treated; and fourwereviremiccontrollers (Table
S1). Patients were grouped into three categories based on viral
loadsand therapy: (1) viremicprogressorswereuntreated individ-
uals with viral loads higher than 2,000 viral RNA copies/ml of
plasma; (2) progressorswere treated individualswhose initial viral
loadswere higher than 2,000 viral RNA copies/ml before therapy;
(3) controllerswere individualswhomaintain low viral loads spon-
taneously in the absence of therapy (<2,000 viral RNA copies/ml).
The frequency of latently infected, resting CD4+ T cells in our pa-
tientswassimilar to that reportedbyothersasmeasuredbyquan-
titative viral outgrowth assay (Table S1 and Laird et al., 2013).
Libraries were produced from genomic DNA by a modification
of the translocation-capture sequencing method that we refer to
in this paper as integration sequencing (Figure 1A) (Janovitz
et al., 2013; Klein et al., 2011). Virus integration sites were recov-
ered by semi-nested ligation-mediated PCR from fragmented
DNA using primers specific to the HIV-1 30 LTR (Table S2).PCR products were subjected to high-throughput paired-end
sequencing, and reads were aligned to the human genome.
Since sonication is random, it produces unique linker ligation
points that identify the specific integration events in each in-
fected CD4+ T cell, which allows both single-cell resolution and
identification of expanded clones of cells with identical integra-
tions (Berry et al., 2012 and Figure 1A). Thus, integration
sequencing can enumerate both the number of integration sites
and the number of infected cells.
A total of 6,719 unique virus integration sites were determined
(Table S3): 873 unique integrations in viremic controllers; 987 in-
tegrations in untreated progressors; and 4,859 integrations in
treated progressors (Figure 1B).
Integrations Are Enriched in Introns of Highly Expressed
Genes
We analyzed the genomic location of the integration sites ob-
tained from viremic controllers and untreated and treated pro-
gressors and compared our results to published data obtained
from HIV-1-infected individuals (Han et al., 2004; Ho et al.,
2013; Ikeda et al., 2007; Schro¨der et al., 2002). In agreement
with the work of others, the majority of integration sites in each
group are genic (Figure 1C and Figure S1A). Moreover,Cell 160, 420–432, January 29, 2015 ª2015 Elsevier Inc. 421
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Figure 2. Identification of Clonally Ex-
panded Cells Bearing Integrated HIV-1
(A) Proportion of viral integrations (Int) that are
clonally expanded, as identified by the same
integration site with multiple shears in controllers
(C) or viremic (V) or treated progressors (T).
(B) Proportion of infected cells deriving from clonal
expansion.
(C) Proportion of clonally expanded (CE) and single
(S) viral integrations in genic or intergenic regions.
(D) Proportion of clonally expanded and single viral
integrations in introns.
(E) Proportion of clonally expanded or single viral
integrations in genes with high, medium, or low
expression. p values refer to proportion of in-
tegrations in highly expressed genes.
(F) Flow cytometry sorting strategy to identify
CD4+ T cell subsets. CM, TM, and EM cell subsets
were identified based on their CD45RA, CCR7,
and CD27 expression. Shown is one representa-
tive sort.
(G) Proportion of viral integrations (Int) that are
clonally expanded, as identified by the same
integration site with multiple shears in sorted CD4+
T cell subsets from patient 9.
(H) Proportion of infected cells deriving from clonal
expansion in sorted CD4+ T cell subsets from pa-
tient 9.
ns, not significant. ***p < 0.0001 using two-pro-
portion z test. See also Figure S2.integrations are found more frequently in the introns of highly ex-
pressed genes, and there is a slight bias for viral orientation that
leads to convergent transcription (Figures 1D, 1E, and 1F and
Figures S1B–S1E) (Mitchell et al., 2004; Schro¨der et al., 2002).
Thus, the general features of integrations defined by integration
sequencing are similar to those obtained by others.
Although the differences between groups were small in
magnitude, they were significant in that treated progressors
had a smaller proportion of integrations in genic regions (p <
0.0001 and p < 0.0001, respectively) and in highly expressed
genes (p < 0.0001 and p < 0.0001, respectively) when compared
to viremic controllers and untreated progressors (Figures 1C
and 1E). Conversely, the proportion of viral integrations in
genes expressed at lower levels was increased in treated
progressors compared to viremic controllers and untreated
progressors (p = 0.002 and p < 0.0001, respectively). Viremic422 Cell 160, 420–432, January 29, 2015 ª2015 Elsevier Inc.controllers and treated progressors were
not significantly different from each other
in terms of the level of expression of the
genes at the sites of integration (Fig-
ure 1E). Thus, therapy is associated with
a relative decrease in the number of cells
with viral integrations in highly expressed
genes.
Identification of Clonally Expanded
Cells Containing Integrated HIV-1
Since we shear DNA ends randomly to
produce our libraries and by paired-endsequencing can determine the precise site of both the integration
and sheared end, we infer that identical integrations with unique
sheared ends arise from clones of expanded cells (Figure 1A). In-
tegrations can therefore be classified as clonally expanded (i.e.,
identical integrations with distinct sheared ends, deriving from
the clonal expansion of an original unique, single integration
event) or single integrations (i.e., unique integration site with a
single sheared end).
Clonally expanded viral integrations were present in all individ-
uals irrespective of therapy or viremia (Table S3). However, the
proportion of clonally expanded viral integrations is significantly
lower in viremic controllers (30%) and viremic progressors (27%)
than in treated progressors (40%) (p < 0.0001 and p < 0.0001,
Figure 2A and Figure S2A). Although the size of individual clones
varied from 2 to 295 cells (Figure S2B), the relative increase in
clonally expanded integrations during therapy consistently
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Figure 3. Clonally Expanded Viral Integra-
tions Increase and Single Integrations
Decrease during Therapy
Graphs show data from patients 1 (blue), 2 (red),
and 3 (green) from longitudinal time points (Table
S1). Time was normalized from 0 to 1 (727 days
pre-therapy to 2617 days post-therapy). Dotted
line at t = 0.21 marks therapy initiation. Trendline
was determined by linear regression model. Solid
lines indicate significant change in proportion of
events; dashed lines indicate insignificant change
in proportion of events.
(A) Proportion of clonally expanded viral in-
tegrations (Int).
(B) Proportion of single viral integrations.
(C) Proportion of genic clonally expanded viral
integrations.
(D) Proportion of genic single viral integrations.
(E) Proportion of intergenic clonally expanded viral
integrations.
(F) Proportion of intergenic single viral integrations.
See also Figure S3.translated into an increase in the number of infected cells that
derive from expanded clones (Figure 2B). The percentage of
cells containing clonally expandedHIV-1 integrations was similar
in untreated progressors (78%) and controllers (79%), but it was
significantly increased in treated progressors (90%) (p < 0.0001
and p < 0.0001, Figure 2B and Figure S2C). Thus, therapy is
associated with an increase in the frequency of clonal HIV-1 in-
tegrations and infected clonally expanded cells.
To determine whether the position of viral integration in the
genome correlates with clonal expansion, we compared the
location of genomic clonally expanded to single integrations.
Both types of integrations favored genes and their introns (Fig-
ures 2C and 2D and Figures S2D and S2E). However, the propor-
tion of clonally expanded integrations in intergenic regions was
greater than that of single integrations (Figure 2C, p < 0.0001).
Moreover, of the integrations in genes, single integrations wereCell 160, 420–432more likely to be found in highly ex-
pressed genes than clonal integrations
(Figure 2E, p < 0.0001, and Figure S2F).
Thus, cells harboring viral integrations in
intergenic regions and genes that are ex-
pressed at lower levels are more likely to
be clonally expanded.
Large Expanded Clones Are Found
in Memory Cells
Central memory cells are thought to be
the major source of the HIV-1 reservoir
(Chomont et al., 2009). To investigate
the nature of the cells that comprise the
expanded clones, we performed virus
integration sequencing on genomic DNA
from sorted central, transitional, and
effector memory CD4+ T cells (Figure 2F).
In both individuals studied, all three sub-
sets of CD4+ T cells contained expandedclones (Figures 2G and 2H and Figures S2G and S2H). Thus,
central, transitional, and effector memory T cells, all of which
have undergone antigen-stimulated cell division, harbor the
expanded clones of HIV-1 integrants.
Clonally Expanded Integrations Increase after Therapy
The proportion of clonally expanded viral integrations is
increased in treated progressors (Figure 2A and Wagner et al.,
2014). To further examine the effect of therapy on clonal expan-
sion, we analyzed longitudinal samples from three typical pro-
gressors before and during therapy (Table S1). We found an
increase in the number of clonally expanded integrations
throughout the treatment period of up to 7.2 years in two of the
three patients (Figure 3A, p = 0.017, and Figure S3A) as well as
an increase in the number of cells that contained clonally
expanded viral integrations (Figure S3B). Correspondingly, there, January 29, 2015 ª2015 Elsevier Inc. 423
was also an overall decrease over time in single integrations (p =
0.017), with a half-life of 127 months assuming a non-linear
regression model for one-phase decay (Figure 3B). Thus, our
data suggest that the numbers of single integrations decay
very slowly over time, while clonally expanded integrations in-
crease with time on cART.
The increase in the number of clonal integrations during cART
did not favor genic or intergenic regions (p = 0.65), indicating that
this effect is independent of the location of the integration in the
genome (Figures 3C and 3E and Figure S3C). In contrast, single
integrations decrease significantly in genic regions (Figure 3D,
p = 0.036, and Figure S3D) and increase proportionally in inter-
genic regions (Figure 3F, p = 0.036). Thus, the fate of cells
harboring single viral integrations in cART treated progressors
differs from clonal integration. Moreover, the fate of single inte-
grations is dependent on their location in the genome, whereas
the clonal integrations are not. These results suggest that cells
bearing genic single integrations are selected against during
therapy and that clonal expansion is not.
Clonally Expanded Integrations in the Same Genes in
Multiple Patients
In the three progressors who provided longitudinal samples,
5% of the clonal integrations persisted through successive
time points without selection for genic or intergenic regions
compared to all clonal integrations (Figures 4A and 4B). Further-
more, of the genic integrations that persisted, there was also no
selection for or against those in highly expressed genes (Fig-
ure 4C). Thus, the persistent clonal integrations are indistinguish-
able from the larger pool of clonally expanded viral integrations in
terms of their position in the genome.
To determine whether specific genes or groups of genes are
permissive for clonal expansion, we looked for overlap in genic
integration sites between samples (Figures 4D–4F). Despite a
higher number of single integrations, there was much greater
overlap of the genes that harbor clonally expanded integrations
between individuals irrespective of treatment or level of viremic
control (p < 0.0001) (Figures 4D–4F). On average, there is 13%
and 3% overlap between genes harboring clonally expanded
and single viral integrations, respectively. The genes containing
clonally expanded viral integrations in multiple patients are ex-
pressed at lower levels than genes containing overlapping single
viral integrations (Figure 4G). Taken together, these results sug-
gest that cells that carry integrations in highly expressed genes
tolerate clonal expansion less well than cells with integrations
in genes with lower levels of expression.
Since clonal integrations have been associated with genes
involved in malignant transformation (Wagner et al., 2014), we
examined our entire dataset for enrichment of integrations in
cancer-associated genes (n = 743 cancer-associated genes
[Vogelstein et al., 2013; Zhao et al., 2013]). Although there was
an overall enrichment for integrations in cancer genes (329/
4,410 = 7.5%) compared to all genes in the human genome
(743/25,660 = 2.8%) (p < 0.0001), this preference does not
seem to be significant because it is similar to the overall prefer-
ence for integration into highly expressed genes (Figure S4).
Furthermore, we observed no overrepresentation of single,
clonal, or persistent integrations in cancer genes (Figure 4H).424 Cell 160, 420–432, January 29, 2015 ª2015 Elsevier Inc.Importantly, a significant decrease in integrations in cancer-
related genes was observed in longitudinal samples (Figure 4I),
suggesting that these are selected against with therapy.
Expanded Clones Contain Defective Viruses
Our method of integration sequencing captures the end of the 30
LTR and identifies the genomic site of viral integration. To deter-
mine whether the viruses found in expanded clones are intact,
we used nested integration site-specific PCR primers that
were anchored in the host genome to amplify the 50 LTRs of 75
expanded clones from eight individuals (Figure 5A and Table
S2). The clones selected for PCR verification varied in size
from5 to 200 out of 0.3–23 106 CD4 T cells. Of the 75 sequences
obtained, 24 showed fragmented 50 LTRs flanked by the correct
genomic site, and an additional 44 of the proviruses did not have
a recoverable 50 end (Figure 5B). The remaining eight viruses with
intact 50 LTRs were amplified in limiting dilution conditions using
integration site-specific primers and HIV-1 primers (Figure 5C).
Three of the eight viruses could not be amplified; four had large
deletions in Env, one had a frameshift mutation in pol, and one
had undergone APOBEC3G-mediated hypermutation to pro-
duce a premature stop codon in env (Figure 5D and Data S1).
Thus, we were unable to find a single intact integrated provirus
among 75 expanded clones.
Hotspots for Virus Integration
Overlap between integrations in the genes of different patients
suggests the existence of hotspots for HIV-1 integration. A num-
ber of individual genes have been identified as preferential sites
for HIV-1 integration, including BACH2, MKL2, DMNT1, MDC1,
and STAT5B (Ikeda et al., 2007; Maldarelli et al., 2014; Wagner
et al., 2014). To identify hotspots for HIV-1 integration genome-
wide, we subjected our dataset to hot_scan analysis (Silva
et al., 2014), which defines hotspots by identifying regions of
local enrichment using scan statistics. This analysis identified
55, 85, and 247 hotspots for controllers, viremic, and treated
progressors, respectively (Figure 6A). For example, the intron
between exons 5 and 6 inMKL2 is a hotspot for integration in pa-
tient 11, contains an expanded clonal family in patient 10, and
was also identified as a site of enrichment for integration by
others (Maldarelli et al., 2014) (Figure 6B).
To validate our in silico analysis and to further characterize the
MKL2 hotspot, we sequenced the gag gene from proviruses in-
tegrated into MKL2 by amplification with nested genomic
primers specific for MKL2 and HIV-1 gag. Sequences obtained
from patient 10, who showed only one expanded clone, are
very closely related to each other, which is consistent with a
single clonally expanded integration (Figure 6C). In contrast, se-
quences obtained from patient 11 are far more diverse, suggest-
ing that there were several different viral integrations in theMKL2
hotspot (Figure 6C). We conclude that the hotspots defined by
hot_scan represent multiple distinct integration events in close
proximity.
Viremic progressors had the highest proportion of integration
events in hotspots, indicating that, in the case of high-level
viremia, therearespecificgenomic locations that favor integration
(Figure 6D). Although themajority of all integrations fall outside of
hotspots (Figure 6D), hotspots resemble other integrations in that
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Figure 4. Integrations in Genes Permissive for Clonal Expansion Occur in Multiple Patients
(A) Percent viral integrations present in more than one time point (persistent integrations) in patients 1, 2, and 3 (Table S1).
(B) Comparison of persistent (P) and clonally expanded (CE) viral integrations in genic or intergenic regions.
(C) Proportion of persistent and clonally expanded viral integrations in genes with high, medium, or low expression. p values refer to proportion of integrations in
highly expressed genes.
(D–F) Heatmap showing overlap between samples of genes containing clonally expanded or single viral integrations between samples. Patients are indicated by
P1-13. Multiple samples from one individual are marked by a bracket. The amount of overlap is denoted by color (see legend); red, 100% overlap.
(G) Genes containing single or clonally expanded viral integrations were analyzed for their presence in multiple patients. Genes with integrations in more than one
individual were classified as ‘‘overlapping’’; genes with integrations in only one individual were classified as ‘‘unique.’’ Shown is the proportion of single and
clonally expanded unique and overlapping viral integrations in genes with high, medium, or low expression. p values refer to proportion of integrations in highly
expressed genes.
(H) Genes with integrations were analyzed for their association with cancer. Proportions of cancer-associated genes are shown for single, clonally expanded, and
persistent viral integrations. The number indicates the total number of genes from each category.
(I) Graph shows proportion of integrations in cancer-related genes from patients 1 (blue), 2 (red), and 3 (green) from longitudinal time points (Table S1). Time was
normalized from 0 to 1 (727 days pre-therapy to 2617 days post-therapy). Dotted line at t = 0.21 marks therapy initiation. Trendline was determined by linear
regression model and indicates significant change in proportion of events. p = 0.023.
ns, not significant. *p < 0.05; **p < 0.01; ***p < 0.0001 using two-proportion z test. See also Figure S4.they arepreferentially foundwithingeneswithapreponderanceof
these in introns (Figures 6E and 6F). In all cases, hotspots are en-
riched in highly expressed genes, and consistent with the overall
decrease in viral integrations in highly expressed genes during
therapy, theproportion of hotspots in thesegenesalso decreases
(Figures 6G and 1E). Thus, the general characteristics of hotspots
are similar to features of all integrations.
To determine whether there is a relationship between hotspots
and clonally expanded viral integrations, we enumerated single
and clonally expanded integrations in hotspots (Figure 6H).Only a small fraction (11%–18%) of all single integrations were
found in hotspots with untreated viremic progressors showing
the highest level (Figure 6H). In contrast, therewas amuch higher
proportion of clonal integrations in hotspots (30%–46%), with
the lowest proportion in treated progressors (Figure 6H). This
observation is consistent with the finding that there is a greater
degree of overlap in genes that harbor clonally expanded rather
than single integrations (Figures 4D–4F) and that clonally
expanded integrations are more likely to be hotspots than single
integrations (Figure 6H, p < 0.0001).Cell 160, 420–432, January 29, 2015 ª2015 Elsevier Inc. 425
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(A) Sequence analysis of 50 LTRs in clonally expanded integrations. Of 75 different clonally expanded integrations from 8 individuals, 24 showed fragmented 50
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Green dot, intact, non-hypermutated sequence; red dot, no PCR product recovered; red triangle, sequence with internal deletion; –, not done. See also Data S1.Viral Integration Enriched in Sites Containing a DNA
Sequence Motif
To determine whether there are specific genomic features asso-
ciated with sites of viral integration and hotspots, we examined
100 base pairs (bp) centered on all integration sites for the pres-
ence of a consensus sequence (Bailey and Elkan, 1994). We
found 7% of all integrations within 100 bp of a highly conserved
30 bp motif (INT-motif) (Figure 7A). The majority of the integra-
tions identified in this analysis were single integration events,
with the ratio of single-to-clonal integrations being significantly
different from the expected (Figure 7B, p < 0.0001). When
HIV-1 integrates directly into the INT-motif, the 50 end of themotif
is recurrently found 20 bp from the site of viral integration (Fig-
ure 7C). The INT-motif is asymmetrically distributed in Alu re-
peats, and its position coincides with a peak of viral integration
(Figure 7D). Furthermore, there is a significant overall enrichment426 Cell 160, 420–432, January 29, 2015 ª2015 Elsevier Inc.of integrations inside Alu repeats (Figure 7E) and in close prox-
imity to Alu repeats, irrespective of whether the integration is
inside genes or in intergenic regions (Figure 7F). Thus, a prefer-
ence for Alu is independent of a preference for integration in
genes.
Previous studies have shown a preference for integration into
Alu repeats, potentially because Alu repeats are enriched in
gene-rich regions (Schro¨der et al., 2002). To further examine
the relationship between Alu repeats and transcription of
genes, we determined the distance between Alu repeats and
the center of all genes. There was no positive correlation be-
tween the position of Alu and the level of transcription
(Figure 7G). To determine whether the distance between inte-
gration and Alu repeats correlates with transcription, we
measured the distance between the sites of integration and
Alu repeats in all genes (Figure 7H). There was no significant
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ns, not significant. *p < 0.05; **p < 0.01; ***p < 0.0001 using proportion test.difference between integration distance to Alu repeats in highly
expressed, silent, or trace level expressed genes. Therefore,
the rate of transcription does not impact integration distance
to Alu repeats, and integration at these sites must be indepen-
dent of transcription.
Finally, the number of Alu repeats in a hotspot is directly corre-
lated with the number of integration events in that hotspot (Fig-
ure 7I, r = 0.86). We conclude that HIV-1 has a preference for
integration in close proximity to sites in the genome that are en-
riched in Alu repeats and that this preference is independent of
the level of transcription.DISCUSSION
CD4+ T cells that are actively infectedwith HIV-1 are rapidly elim-
inated during anti-retroviral therapy, but this form of treatment is
relatively ineffective in selecting against latently infected CD4+
T cells, which have an estimated half-life of 44 months. Abolish-
ing the latent reservoir is the current hurdle to finding a cure for
HIV-1 infection. Although we have learned a great deal about
the location of the latent compartment and its persistence during
therapy, it has been difficult to uncover whether there are spe-
cific genomic features associated with latency (Siliciano andCell 160, 420–432, January 29, 2015 ª2015 Elsevier Inc. 427
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428 Cell 160, 420–432, January 29, 2015 ª2015 Elsevier Inc.Greene, 2011). One of the major impediments to understanding
latency is our inability to purify cells harboring latent HIV-1 as
opposed to cells containing defective viruses. To further investi-
gate the latent compartment, we used a high-throughput
method that uncovers sites of HIV-1 integration while enumer-
ating clones of expanded T cells that bear identical integrations.
By comparing HIV-1 integration in controllers and untreated
and treated progressors, including longitudinal samples ob-
tained before and after therapy, we found that proliferating
clones of infected cells accumulate over time. However, we
were unable to detect intact, full-length viral sequences in these
clones. Instead, our evidence suggests that the reservoir resides
primarily in cells bearing unique integrations that are selected
against by cART in an integration-specific manner, favoring the
persistence of integrations in intergenic regions and silent genes,
with decay kinetics that argue against homeostatic proliferation.
A number of different investigators have shown that HIV-1 pre-
fers to integrate into the introns of highly expressed genes (Crai-
gie and Bushman, 2012). This is true for all of the individuals in
our study irrespective of their status as controllers or treatment
with cART. Although the level of intrinsic viremic control has no
detectable effect on integration site selection, therapy selects
against genic integrations and, more specifically, against inte-
grations in highly expressed genes, when compared to un-
treated progressors or controllers. Given that cART selects for
cells that bear silent proviruses, the results suggest that viruses
integrated into genes are less likely to become latent than those
found in intergenic regions. Moreover, the data indicate that,
among the proviruses integrated into genes, those that are found
in genes expressed at low levels are also more likely to become
latent. These findings are entirely consistent with in vitro(C) Conserved integration site within INT motif. Histogram maps the start site
(50 end) of INT motif with respect to the integration site (dotted line). Peak
shows that the majority of integration sites occur 20 bp from the 50 end of the
motif start site. Shaded region represents the location of the INT motif relative
to the majority of the integration sites.
(D) Location of integration preference and INT-motif inside Alu repeats is
overlapping. (Left) Location of integration site Alu repeats were plotted relative
to the midpoint of the repeat. (Right) The location of the start site of INT motifs
within Alu repeats.
(E) Integrations are enriched inside Alu repeats. Total integrations identified
inside Alu repeats were enumerated (red diamond) and compared to the ex-
pected value as defined by Monte Carlo simulation. The boxplot displays the
variation of the number of random integrations identified inside Alu repeats by
each iteration of the simulation.
(F) Integrations are near Alu repeats in genes and intergenic regions. Average
distance to the nearest Alu repeat for all integrations inside genes or intergenic
regions was calculated (red diamond) and compared to the expected distance
as defined by Monte Carlo simulation. The boxplot displays the variation of the
distance of random integrations from Alu repeats in genes or intergenic re-
gions by each iteration of the simulation.
(G) Distance to Alu repeats from the center of highly, medium, low, trace, or
silently expressed genes.
(H) Distance to Alu repeats in highly, medium, low, trace, or silently expressed
genes.
(I) Positive correlation between Alu repeats and integrations inside hotspots.
Graph shows number of Alu repeats (x axis) versus integrations in hotspots
(y axis). Hotspots not containing Alu repeats were removed from this analysis.
The scatter plot shows the linear relationship between the number of INT
motifs and integrations inside hotspots (Pearson’s correlation, r = 0.86).
experiments in cell lines showing that level of HIV-1 transcription
is dependent, in part, on the status of surrounding chromatin
(Jordan et al., 2003; Jordan et al., 2001; Sherrill-Mix et al., 2013).
HIV-1 integration has been studied in multiple cell types, but
large libraries of integrations sites in primary infected T cell
have only recently become available (Maldarelli et al., 2014;
Wagner et al., 2014). Integration sites obtained from in-vitro-in-
fected cell lines and primary T cells are distinct (Brady et al.,
2009; Sherrill-Mix et al., 2013). Nevertheless, common features
of HIV-1 integration have been defined, including the observation
that integration favors Alu repeats (Schro¨der et al., 2002). This
association was thought to be dependent on the presence of
these repeats in the introns of gene-rich regions and not on a
particular sequence feature (Schro¨der et al., 2002). However,
we observed that integration preference into highly transcribed
genes and into Alu repeats seem to be independently important,
and furthermore, integrations are enriched near Alu repeats both
in genic and intergenic regions. One possible explanation for
preference for Alu seems to be the presence of an INT motif.
TG-(N)5-7-CA sequence has been associated with sites of
HIV-1 integration, but an integration consensus has not been
defined (Brady et al., 2009; Holman and Coffin, 2005; Lewinski
et al., 2006; Serrao et al., 2014; Wang et al., 2007; Wu et al.,
2005). We found a 30 bp INT motif within 100 bp of 7% of all in-
tegrations, the large majority of which are single events. As ex-
pected, the HIV-1 INT motif contains a signature TG-(N)5-7-CA
and can form a hairpin structure, anchored on 50 NTG-30, 50
CAN-30. This motif is frequently found at the 30 end of Alu, where
it coincides with a peak of viral integration events, and viruses in-
tegrated directly in this motif show a dramatic specificity for
insertion site. The asymmetric peak and specificity of the inte-
gration site are remarkable. Nevertheless, we are likely underes-
timating the frequency of integrations within Alu because we can
only map unique reads.
The observation that HIV-1 prefers to integrate in the neighbor-
hood ofAlu repeats is consistent with the finding that different in-
dividuals have been reported to have multiple integrations in
selected genes (Ikeda et al., 2007; Maldarelli et al., 2014;
Schro¨der et al., 2002; Wagner et al., 2014). Our experiments
define a group of overlapping hotspots for integration that share
many of the features of all HIV-1 integrations, including prefer-
ence for introns of highly expressed genes and high density of
Alu repeats. Viremic progressors showed the highest levels of
hotspot integration, possibly because persistent integration
leads to over-representation of these favored sites. Alternatively,
these integrations might be positively selected by mechanisms
that remain to be determined.
Individuals receiving cART show increasing numbers of cells
with identical viral genomes by SGA, suggesting clonal expan-
sion of a subset of cells bearing integrated proviruses (Buzon
et al., 2014; Chomont et al., 2009; Wagner et al., 2013). Two in-
dependent groups have recently documented the long-term
persistence of expanded clones of cells during therapy with
cART (Maldarelli et al., 2014; Wagner et al., 2014). Our analysis
confirms and extends these observations by showing that,
when considered as a group, expanded clones are less likely
to occur when the provirus is in a genic region, and clones that
are associated with genes tend to be in genes that are expressedat lower levels than single integrations. Thus, proviruses inserted
into active regions of the genome, which would be more likely to
support viral re-activation during T cell proliferation, are generally
selected against during clonal expansion.
Why certain integration sites are permissive for clonal expan-
sion is not known, but finding that expanded clones with integra-
tions occur in cancer-related genes led to the suggestion that
integration into genes that regulate cell division promotes prolif-
eration (Wagner et al., 2014). While we also found a higher pro-
portion of integrations in cancer-related genes as compared to
random, this bias was not different from that observed for other
highly expressed genes favored by HIV-1. Further, we do not see
any differential bias for integration in cancer-related genes in
clonally expanded cells compared to single integrations and an
overall decrease in the number of integrations in cancer related
genes during the course of therapy. Since the number and size
of clones increase with time on therapy, the data indicate that
integration into cancer genes is unlikely to be a general contrib-
utor to the proliferation of infected cells.
Our data show that cART selects for expanded clones and that
viremic controllers resemble treated progressors in showing a
higher proportion of expanded clones than untreated viremics.
cART selects for clonal integrations irrespective of the location
in the genome. This is in contrast to single integrations, which
are selected against by therapy. cART specifically favors the sur-
vival of single integrations in intergenic regions and is biased
against genic regions, with an overall half-life for single integra-
tions of 127 months. The half-life of single integrations is not
too dissimilar from the current estimate for the latent reservoir,
which is believed to decay with a half-life of 44 months on
cART (Finzi et al., 1999).
The major outstanding question after the discovery of clonally
expanded cells with integrated HIV-1 is whether the virus from
these cells contributes to the latent reservoir (Maldarelli et al.,
2014; Wagner et al., 2014). Several different independent lines
of evidence argue against this idea. First, although the latent
reservoir is thought to be contained primarily in resting central
memory CD4+ T cells (Siliciano and Greene, 2011), we find that
clonally expanded viral integrations are found in all threememory
T cell compartments. Second, whereas the reservoir appears to
decay with time on cART, we find that clonally expanded integra-
tions increase with time and do so irrespective of whether they
are found in genes or intergenic regions. In contrast, single inte-
grations in more active parts of the genome, which are more
likely to support HIV-1 reactivation, are selected against with
time on ART. Finally, all 75 of the clonally expanded proviruses
tested were defective, which is in agreement with two examples
in the literature (Imamichi et al., 2014; Josefsson et al., 2013).
Thus, we conclude that intact virus is not enriched in infected
expanded cells. However, we cannot rule out the possibility
that a rare clone of cells contains an active virus. Nevertheless,
the 90% of all cells bearing integrated proviruses that account
for expanded clones of infected cells in cART-treated progres-
sors appear unlikely to be the major source of the rebounding
latent reservoir. Instead, the replication-competent reservoir is
likely to be contained in the remaining 10% of cells that harbor
single integrations that decline with a long half-life on cART
(Figure S5).Cell 160, 420–432, January 29, 2015 ª2015 Elsevier Inc. 429
In conclusion, the data indicate that HIV-1-infected T cells
that undergo clonal expansion are able to do so because their
proviruses are defective and that the replication-competent
reservoir is found in the subset of CD4+ T cells that remain
quiescent.EXPERIMENTAL PROCEDURES
CD4+ T Cell Isolation for Integration Library Construction
Human samples were collected after signed informed consent in accordance
with Institutional Review Board (IRB)-reviewed protocols by all participating in-
stitutions. Patients 1, 2, and 3 were selected from the Seattle HIV longitudinal
cohort studies at Fred Hutchinson Cancer Research Center. Patients 4, 8, and
9 were recruited from the University of Cologne, and samples were obtained at
Rockefeller University (MNU_0628). Patients 5, 6, and 7were selected from the
Rockefeller University HIV-1 antibody therapy clinical trial. Patients 10, 11, 12,
and 13 were selected from a group of elite controllers that were followed at the
Ragon Institute in Boston.
CD4+ T cells were isolated from whole PBMC using anti-CD4 microbeads
(Miltenyi Biotec). The percentage of live cells was determined by flow cytom-
etry based on forward and side scatter. Purity of CD4+ T cells was determined
by labeling isolated cells with anti-human CD3, CD4, CD8, CD19, and HLA-DR
and gating on CD3, CD4 double-positive cells. Isolated cells were used for
library construction only if purity was >75%. CD4+ T cell subsets were isolated
by FACSorting on a BD Aria II by labeling cells with anti-human CD3, CD4,
CD8, CD66b, CD335, HLA-DR, CCR7, CD27, and CD45RA. Analysis of
CD4+ T cell subsets was done by pooling cellular DNA isolated from multiple
sorts of the same sample.
Quantitative Viral Outgrowth Assay
Viral outgrowth was performed as previously described. (Laird et al., 2013)
Integration Library
The method for integration library construction was adapted from TC-Seq
(Klein et al., 2011).
DNA Preparation
DNA from 0.2–2 million CD4+ cells from HIV-1-infected patients was isolated
and prepared as previously described (Klein et al., 2011). Fragments were
ligated to 200 pmol of annealed linkers (Table S2). Virus sequences were elim-
inated by digestion with BglII (NEB), and fragments were purified.
Integration Site Amplification
Semi-nested ligation-mediated PCR was performed on DNA. All PCRs were
performed using Phusion Polymerase (Thermo). DNA was divided into 700 ng
aliquots and subjected to single-primer PCR with biotinylated LTR1 [ 1 3
(98C-1 min) 12 3 (98C-15 s, 62C-30 s, 72C-30 s) 1 3 (72C-5 min)] (Table
S2). Each reaction was spiked with pLinker and subjected to additional
cycles of PCR [1 3 (98C-1 min) 25 3 (98C-15 s, 62C-30 s, 72C-30 s) 1 3
(72C-5 min)]. Products of 300–1,000 bp were isolated by agarose gel electro-
phoresis and magnetic streptavidin bead purification. Semi-nested PCR was
performed on the magnetic beads first with a single primer LTR2 (same
cycling conditions as above) followed by spiking in pLinker and additional
cycles (Table S2). Products of 300–1,000 bp were isolated by gel
electrophoresis.
Paired-End Library Preparation
Linkers were digested by AscI such that a six-nucleotide barcode (CGCGCC)
was left on the DNA fragments, indicating linker-dependent amplification.
Fragments were blunted by End-It DNA Repair Kit (Epicenter), purified
with AmPure beads (Agencourt), and ligated to NextFlex paired-end adapters.
Adaptor-ligated fragments were enriched by 35 cycles of PCR with NextFlex
primers [1 3 (98C-1 min) 35 3 (98C-15 s, 66C-30 s, 72C-30 s) 1 3 (72C-
5min)], and fragments between 300–1,000 bpwere isolated by gel electropho-
resis. Two or three libraries were mixed in equimolar ratios and sequenced by
either 150 bp paired-end sequencing on Illumina MiSeq or 150 bp or 100 bp
paired-end sequencing on an Illumina 2500 HiSeq. Data are accessible via
NCBI SRA using the accession number: SRP045822.430 Cell 160, 420–432, January 29, 2015 ª2015 Elsevier Inc.Computational Analysis
Read Alignment
Paired-end reads were mapped to the HIV-1 sequence (designated as a bait)
using BLAT (Kent, 2002) with default settings. Reads that were mapped to the
bait withoutmismatcheswere checked for the linker barcode in the paired-end
read and were mapped to the human genome reference GRCh37/hg19 with
Bowtie (Langmead et al., 2009). Only uniquely mapped reads (allowing for
up to two mismatches) were used as defined in the best alignment stratum
(command line options: -v2 -all -best -strata -m1). Identical reads generated
by PCR amplification were merged.
Integration Determination
Once the paired-end reads were properly mapped in the bait and human
genome (see above), we determined the integration breakpoint by aligning
the remaining nucleotide sequence containing the 30 terminus of the HIV-1
LTR to the human genome using BLAT (default settings). Only uniquely map-
ped reads up to 1 Kb away from its partner were kept. Adjacent (within 50
nucleotides) putative integrations sites were merged. Finally, the 50 end of
the paired-end reads were used to deduce the integration and shear position
sites in the human genome.
Hotspot Detection
To detect preferred sites of HIV-1 integration genome wide, we subjected our
dataset to hot_scan software analysis (Silva et al., 2014), which defines hot-
spots by scan statistics. Hotspots obtained by hot_scan were defined using
different window widths (100, 200, 500, 1,000, 2,000, 5,000, 10,000, 20,000,
50,000, and 100,000 bp).
Motif Analysis
To determine a consensus motif, 100 bp flanking each integration site was
analyzed for the presence of 30 bp consensus sequence using MEME soft-
ware (Bailey and Elkan, 1994).
Monte Carlo Simulation for Virus Integration and Hotspots
Monte Carlo simulation was conducted by shuffling the genomic locations
of all virus integration sites 10,000 times using bedtools shuffle utility
(Quinlan and Hall, 2010). Then, we compared the observed number with
the median number of integrations in the randomized list. We assessed
enrichments by p value by counting the frequency of observed events
being equal to or higher than the number of randomized events divided by
n = 10,000.
Statistical Analysis
Proportion test is the standard test for the difference between proportions,
also known as a two-proportion z test. We used R’s implementation of this
via the prop.test() function.Integration Library Verification
To verify our integration sequencing strategy, we constructed two libraries
from DNA isolated from un-infected individuals. We recovered 13 sequences
that mapped to integration sites. We subtracted these ‘‘integration sites’’
from all libraries before proceeding.
To test the saturation of our method, two separate integration libraries were
constructed from identical samples for three patients. We found that both li-
braries contained the same expanded clonal families, but the majority of single
virus integrations were unique to each sample of cells used for library con-
struction. Single viral integrations found in both libraries were less than 1%
of observed viral integrations.
PCR Verification
Genomic DNA isolated as described was serially diluted and subjected to
nested-PCR using genomic specific primers and primers LTR1 and LTR2
(Table S2) using HotStart Taq Polymerase (QIAGEN) [1 3 (98C-14 min) 40 3
(98C-30 s, 55C-30 s, 72C-30 s) 1 3 (72C-5 min)]. Products were isolated by
gel electrophoresis and sequenced directly. Analysis of clones in this manner
identified that we underestimate the size of clones by four to five times (data
not shown).CD4+ T Cell Subset Sorting
To isolate CD4+ subsets, we labeled PBMCs with antibodies to CD45RA, CD4,
CD8 CD66b, CCR7, CD335, HLA-DR, CD3, and CD27. We separated T cell
subsets by FACS Aria (BD Biosciences) to very high purity (>98%).
Virus Sequencing
50 LTR
50 LTRs from large clones were amplified with nested genomic primers and
LTR2Rev (Table S2) using Platinum High Fidelity Taq (Invitrogen) [1 3 (98C-
14 min) 40 3 (98C-30 s, 55C-30 s, 68C-1 min) 1 3 (68C-5 min)]. Products
were isolated by gel electrophoresis and sequenced directly.
Full-Length Virus
Full-length genomic DNA from infected patients was isolated as described and
serially diluted. Each well was filled to a final volume of 50 ml with PCR reaction
mixture (Platinum TaqMasterMix, Invitrogen) and primers to amplify virus from
a specific integration site in the genome (Table S2 and Ho et al., 2013) using
touchdown cycling to increase specificity. Then, 2ml aliquots from the first
PCR were subjected to nested genomic PCR and 1% gel electrophoresis.
The positive wells were gel purified, and fragments were sequenced directly.
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